^
Association details:
| Biomarker: | BTK C481S |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | SRX3262 (BTK inhibitor, PI3K inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
Published date:
07/30/2021
Excerpt:
In further support, SRX3262 treatment led to an increase in apoptotic cell death in either JeKo-1 BTK-WT or Ibrutinib-resistant cells JeKo-1 BTK-C481S and Mino BTK-C481S (Figures 4E and 4F). In contrast, Ibrutinib failed to induce apoptosis at the same concentrations as SRX3262, up to 5 μM.
DOI:
10.1016/j.isci.2021.102931
